Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Nanoliposomes, Liposomes and Solid Lipid Nanoparticles: Novel Drug Delivery Strategies
share announcement

Nanoliposomes, Liposomes and Solid Lipid Nanoparticles: Novel Drug Delivery Strategies

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (23 October 2023) | Viewed by 2440

Special Issue Editor

Dr. Amal El-Kamel

E-Mail Website
Guest Editor
Department of Pharmaceutics, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
Interests: drug delivery systems; microparticles; nanoparticles; nanocapsules; nanofibers; nanoemulsions; drug targeting

Special Issue Information

Dear Colleagues,

This Special Issue emphasizes new research avenues and recent developments in the application of nanoliposomes, liposomes, and solid lipid nanoparticles, including diagnostics, targeted therapy, and gene and peptide delivery. Surface modifications of these systems may further provide unique features such as enhanced targeting capability. Pharmaceuticals, cosmetics, and nutraceuticals can all be delivered using this class of delivery systems to treat many genetic, communicable, and non-communicable diseases. The aforementioned nanosystems can be used to modify drug absorption, reduce metabolism, prolong half-life, and reduce drug toxicity. Other advantages include being simple to scale up, biocompatible, biodegradable, and nontoxic, as they are formulated from acceptable biocompatible excipients. Hence, you are invited to participate by submitting original research or review articles to this Special Issue, helping to advance this groundbreaking topic.

Dr. Amal El-Kamel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gene therapy
  • protein delivery
  • nutraceuticals
  • theragnostic
  • bioavailability
  • cancer
  • infections
  • Alzheimer’s disease

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

23 pages, 2664 KiB  
Review
Lipidic Nanoparticles, Extracellular Vesicles and Hybrid Platforms as Advanced Medicinal Products: Future Therapeutic Prospects for Neurodegenerative Diseases
by Maria Tsakiri, Ioannis Tsichlis, Cristina Zivko, Costas Demetzos and Vasiliki Mahairaki
Pharmaceutics 2024, 16(3), 350; https://doi.org/10.3390/pharmaceutics16030350 - 01 Mar 2024
Viewed by 1036
Abstract
Neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, affect a wide variety of the population and pose significant challenges with progressive and irreversible neural cell loss. The limitations of brain-targeting therapies and the unclear molecular mechanisms driving neurodegeneration hamper the possibility of developing successful [...] Read more.
Neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, affect a wide variety of the population and pose significant challenges with progressive and irreversible neural cell loss. The limitations of brain-targeting therapies and the unclear molecular mechanisms driving neurodegeneration hamper the possibility of developing successful treatment options. Thus, nanoscale drug delivery platforms offer a promising solution. This paper explores and compares lipidic nanoparticles, extracellular vesicles (EVs), and hybrid liposomal–EV nanoplatforms as advanced approaches for targeted delivery to combat neurodegeneration. Lipidic nanoparticles are well-characterized platforms that allow multi-drug loading and scalable production. Conversely, EVs offer the ability of selectively targeting specific tissues and high biocompatibility. The combination of these two platforms in one could lead to promising results in the treatment of neurodegeneration. However, many issues, such as the regulatory framework, remain to be solved before these novel products are translated into clinical practice. Full article
(This article belongs to the Special Issue Nanoliposomes, Liposomes and Solid Lipid Nanoparticles: Novel Drug Delivery Strategies)
►▼ Show Figures

Figure 1

27 pages, 4494 KiB  
Review
Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand
by Vladimir Temchura, Jannik T. Wagner and Dominik Damm
Pharmaceutics 2024, 16(1), 24; https://doi.org/10.3390/pharmaceutics16010024 - 23 Dec 2023
Viewed by 1083
Abstract
Infectious diseases are a predominant problem in human health. While the incidence of many pathogenic infections is controlled by vaccines, some pathogens still pose a challenging task for vaccine researchers. In order to face these challenges, the field of vaccine development has changed [...] Read more.
Infectious diseases are a predominant problem in human health. While the incidence of many pathogenic infections is controlled by vaccines, some pathogens still pose a challenging task for vaccine researchers. In order to face these challenges, the field of vaccine development has changed tremendously over the last few years. For non-replicating recombinant antigens, novel vaccine delivery systems that attempt to increase the immunogenicity by mimicking structural properties of pathogens are already approved for clinical applications. Lipid-based nanoparticles (LbNPs) of different natures are vesicles made of lipid layers with aqueous cavities, which may carry antigens and other biomolecules either displayed on the surface or encapsulated in the cavity. However, the efficacy profile of recombinant LbNP vaccines is not as high as that of live-attenuated ones. This review gives a compendious picture of two approaches that affect the immunogenicity of recombinant LbNP vaccines: (i) the incorporation of immunostimulatory agents and (ii) the utilization of pre-existing or promiscuous cellular immunity, which might be beneficial for the development of tailored prophylactic and therapeutic LbNP vaccine candidates. Full article
(This article belongs to the Special Issue Nanoliposomes, Liposomes and Solid Lipid Nanoparticles: Novel Drug Delivery Strategies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop